Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04803318

Enrollment

100

Registered

2021-03-17

Start date

2021-01-01

Completion date

2037-01-01

Last updated

2024-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Solid Tumor, Adult

Keywords

Hepatocellular Carcinoma;Lung Cancer, Trametinib, Everolimus, Lenvatinib

Brief summary

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Detailed description

The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.

Interventions

DRUGCombination of three inhibitors Trametinib, Everolimus and Lenvatinib

Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

To treat recurrent or refractory advanced solid tumors with multiple targeting drugs that inhibit several critical signaling pathways in cancer cells.

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Recurrent/Refractory advanced solid tumors * Age between 18 and 85 years * Expected life expectancy is greater than three months

Exclusion criteria

* Benign tumor * Life expectancy is less than three months * Serious medical commodities * others

Design outcomes

Primary

Measure	Time frame
Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.	up to 36 months

Secondary

Measure	Time frame	Description
Assessing progress free survival	48 months	—
Assessing overall survival	48 months	Assessing overall time to survival.

Countries

China

Contacts

Primary ContactZhenfeng Zhang, MD, PhD

zhangzhf@gzhmu.edu.cn+862039195966

Backup ContactBingjia He, MD